Data / Drug companies / Terumo Corporation
Terumo Corporation: 12 products in the FDA NDC directory, labeler code 53877
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Terumo Corporation (labeler code 53877) lists 12 products in the FDA National Drug Code Directory. By type: 7 prescription drugs, 5 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on March 3, 2026.
The request: Watch Terumo Corporation (FDA labeler code 53877): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 53877
- Products in commercial distribution
- 12
- Packages
- 12
- Finished drugs by generic name
- 0
- Prescription products
- 7
- Over the counter products
- 0
- Flagged as original packager
- 7 of 7 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- December 14, 2009
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 7 | 58.3% |
| Drugs for further processing | 5 | 41.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 7 | 58.3% |
| Drugs for further processing | 5 | 41.7% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 5 | 41.7% |
| Kit | 4 | 33.3% |
| Solution | 3 | 25% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Anti-coagulant | 3 |
| Calculi Dissolution Agent | 3 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Lecanemab | 53877-902 | Injection, solution | Drugs for further processing | March 3, 2026 |
| Lecanemab | 53877-901 | Injection, solution | Drugs for further processing | August 26, 2024 |
| Adalimumab | 53877-803 | Injection, solution | Drugs for further processing | July 1, 2023 |
| Adalimumab | 53877-802 | Injection, solution | Drugs for further processing | July 1, 2023 |
| Adalimumab | 53877-801 | Injection, solution | Drugs for further processing | July 1, 2023 |
| Teruflex blood bag system with diversion blood sampling arm 70 ml cpda-1 | 53877-110 | Solution | New drug applications (NDA) | May 22, 2012 |
| TERUFLEX BLOOD with Diversion Blood Sampling Arm 70 mL CPDA-1 | 53877-109 | Solution | New drug applications (NDA) | May 22, 2012 |
| IMUFLEX WB-SP Blood Bag System with Integral Whole Blood Leukocyte Reduction Filter (Saving Platelets) with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) and OPTISOL (AS-5) Red Cell Preservative for collection of 500mL of Blood | 53877-105 | Kit | New drug applications (NDA) | December 15, 2010 |
| TERUFLEX Blood Bag System with Diversion Blood Sampling Arm Anticoagulant CPD with OPTISOL Red Cell Preservative Solution for Collection of 500mL of Blood | 53877-103 | Kit | New drug applications (NDA) | May 5, 2010 |
| TERUFLEX Blood with Diversion Blood Sampling Arm Anticoagulant CPD with OPTISOL Red Cell Preservative for Collection of 450mL of Blood | 53877-101 | Kit | New drug applications (NDA) | May 5, 2010 |
| IMUFLEX WB-RP Blood Bag System with Integral Whole Blood Leukocyte Reduction Filter (Removing Platelets) with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative | 53877-006 | Kit | New drug applications (NDA) | February 26, 2010 |
| TERUFLEX Blood Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1) for Collection of 450mL of Blood | 53877-108 | Solution | New drug applications (NDA) | December 14, 2009 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.